首页> 外文期刊>International Urogynecology Journal >Three-year outcomes of Uretex Urethral Support System for treatment of stress urinary incontinence
【24h】

Three-year outcomes of Uretex Urethral Support System for treatment of stress urinary incontinence

机译:Uretex尿道支持系统治疗压力性尿失禁的三年结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To assess the medium-term performance of the Uretex Urethral Support System, patients were evaluated by the 1-h pad test, cough stress test (CST), Valsalva leak-point pressure test (VLPP), and validated questionnaires. Seventy-five patients were enrolled; median follow-up was 3.6 years (range, 3.1–4.3 years). All patients had a negative CST, 65 (87%) had no leakage during VLPP, and 62 of 72 patients (86%) had a negative 1-h pad test. Compared with baseline values of 50.0 and 28.6, median Urogenital Distress Inventory and Incontinence Impact Questionnaire-7 scores at 3-year follow-up were 16.7 and 0, respectively (P < 0.001). Observed medium-term morbidity included de novo urgency in four (5%), frequency in three (4%), and urge incontinence in one (1%). No patients reported graft erosion. The Uretex Urethral Support System is highly effective (both objectively and subjectively) for treatment of stress urinary incontinence and improves quality of life in women with minimal adverse sequelae.
机译:为了评估Uretex尿道支持系统的中期性能,通过1小时垫试验,咳嗽压力试验(CST),瓦尔瓦尔漏点压力试验(VLPP)和经过验证的问卷对患者进行了评估。纳入患者75例;中位随访时间为3.6年(范围3.1-4.3年)。所有患者的CST阴性,VLPP期间65例(87%)无渗漏,72例患者中的62例(86%)的1h垫试验阴性。与基线值50.0和28.6相比,在3年随访中,泌尿生殖器窘迫清单和失禁影响问卷7的中位数分别为16.7和0(P <0.001)。观察到的中期发病率包括新生尿急(4%)(5%),尿频(3%(4%))和急迫性尿失禁(1%)。没有患者报告移植物侵蚀。 Uretex尿道支持系统在客观和主观上均能有效治疗压力性尿失禁,并改善了女性后遗症的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号